Clinical trials
for patients
Learn about available clinical trials



-
June 30, 2025Pamplona/MadridIn recruitmentEarly phase
D967VC00001 Trastuzumab Deruxtecan trial for the treatment of selected HER2-expressing tumors.
We are conducting this trial to learn more about how trastuzumab deruxtecan could provide benefits to cancer patients. The purpose of this trial is to determine the efficacy and safety of the trial drug for the treatment of a type of locally advanced solid cancer based on the level of HER2 protein expression and, in addition, to learn more about the disease being studied and the associated health problems. -
June 30, 2025PamplonaIn recruitmentEarly phase
1438-0001 Clinical trial to evaluate different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3
The objective of this study is to determine the most appropriate dose of BI 764532 to be received in the future by patients with a cancer like yours who progressed after treatment with available standard treatments, including platinum therapy, or who are ineligible for available standard treatments. Only patients confirmed positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study. -
June 30, 2025Pamplona/MadridIn recruitment
-
June 23, 2025Pamplona/MadridIn recruitment
MCLA-129-CL01 Clinical trial of MCLA-129 in patients with advanced NSCLC and other solid tumors
The aim of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug. -
June 23, 2025Pamplona/MadridIn recruitmentEarly phase
RAY902CT Unmasked assay of RAY21 to inhibit the classical complement pathway in immunological diseases
The main objective is to evaluate the safety and tolerability of multiple s.c. administrations of RAY121 in patients with complement immunodeficiencies -
June 17, 2025Pamplona/MadridIn recruitment
20210181 Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and tolerability of maridebart cafraglutide in adult participants without type 2 diabetes mellitus who are obese or overweight.
This study is being conducted to test whether maridebart cafraglutide [MariTide (formerly AMG 133)] is a safe drug, can reduce body weight, and can improve weight-related conditions in people like you who are living with obesity or being overweight, but do not have type 2 diabetes (T2DM, a disease that occurs when blood sugar levels are too high). -
June 16, 2025PamplonaIn recruitmentEarly phase
MPSA-153-002 EC in combination of NMS-01940153E and atezolizumab with or without prior low-dose decitabine for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors.
The aim of this study is to learn about the safety, tolerability and antitumor properties of NMS-01940153E administered with atezolizumab and with or without decitabine for the treatment of hepatocellular carcinoma (HCC). -
June 16, 2025Pamplona/MadridIn recruitment
CP-START-001 Phase I/II human clinical trial of STAR0602 in patients with inoperable, locally advanced or metastatic antigen-rich inoperable solid tumors.
The main objective is to evaluate the safety/tolerability and toxicity of STAR0602 and to determine the recommended dose for Phase 2 (RP2D) of STAR0602. -
June 11, 2025PamplonaIn recruitmentEarly phase
64042056ALZ2001 Trial of JNJ-64042056, an active immunotherapy directed against phosphorylated tau in participants with preclinical Alzheimer's disease.
The purpose of this study is to evaluate the safety and efficacy of JNJ-64042056 in slowing the progression of Alzheimer's disease (AD) in individuals with preclinical AD. Having preclinical Alzheimer's disease means being in an early stage of the disease in which signs of memory problems are not yet apparent. At this stage, elevated levels of abnormal proteins (amyloid and tau) may be detected in the blood, cerebrospinal fluid or on a PET scan. -
June 6, 2025MadridIn recruitment
MK-5909-003 Phase 1b/2 clinical trial to evaluate safety and efficacy of raludotatug deruxtecan, with or without other drugs in participants with high-grade serous epithelial ovarian carcinoma, primary peritoneal carcinoma or tubal carcinoma.
The main objective is to evaluate the safety and tolerability of raludotatug deruxtecan (R-DXd) administered in combination with carboplatin in participants with recurrent high-grade ovarian carcinoma.